BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
SNCA
,
glucose metabolic process
,
HIV infection
,
Embryo
,
Holistic medicine
,
Aspirin
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
cac10 vcmmae
Summary
General Info
Curated Studies
Most Correlated Studies
There were no matches for cac10 vcmmae
Explore Curated Studies Results
Literature
Most Relevant Literature
Brentuximab-induced hand-foot syndrome in a Hodgkin lymphoma patient.
Brentuximab vedotin use in a jaundiced case with resistant Hodgkin lymphoma.
Practical method development for the separation of monoclonal antibodies and antibody-drug-conjugate…
Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systema…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+…
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by…
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lympho…
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Re…
Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphom…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ